Researchers are looking for a better treatment for people suffering from advanced lung cancer that has certain specific genetic changes ("HER2 mutation"). Advanced non-small cell lung cancer (NSCLC) is a group of lung cancer types that have already spread to nearby tissues outside the lung or to other parts of the body. The chance of curing or controlling this with available therapy is low. HER2 is a protein that promotes the growth and spread of cells. When it is genetically altered, the altered HER2 promotes this even more. We expect BAY 2927088 to block the altered HER2, which should stop the spread of lung cancer. The main purpose of this study is to investigate how well BAY 2927088 works and how safe it is compared to standard therapy in patients with advanced NSCLC with HER2 genetic alterations (mutations). Patients will receive either BAY 2927088 in tablet form 2 times daily, or standard therapy, which is administered via infusion into the veins, in cycles of 21 days. The therapy will continue as long as patients benefit from the treatment and do not have severe side effects or until the treating physician or the patient decides to stop the therapy. Throughout the study, images will also be taken using computed tomography, magnetic resonance imaging, PET scanning, or X-rays. Additionally, health will be monitored in general, blood and urine tests will be performed, and heart activity will be checked with ECG. Patients will also need to fill out questionnaires.


Advanced non-small cell lung cancer || HER2 mutation | Study 22615 | Bayer - Clinical Trials Explorer